It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

The U.S. Preventive Services Task Force pitched an update to its guidelines for cervical cancer screening, endorsing HPV ...

Spruce Biosciences has trimmed the only drug from its pipeline in the wake of a second phase 2 failure this year, leaving the ...

Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of ...

Cellectar Biosciences is laying off 60% of its employees and halting work on its sole clinical-stage radiotherapy after the ...

Less than a year after completing a series B extension round, Angitia Biopharmaceuticals has set its sights even higher with ...

A Maryland jury has convicted both former CytoDyn CEO Nader Pourhassan, Ph.D., and ex-Amarex CEO Kazem Kazempour on several ...